Bridge Biotherapeutics Revenue

Biotechnology Research • 58, Pangyo-ro 255 beon-gil, Korea, Republic of • 11-20 Employees

Bridge Biotherapeutics revenue & valuation

Annual revenue	$1,625,545
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$5,300,000
Total funding	No funding

Key Contacts at Bridge Biotherapeutics

Sungchan Jeong

Senior Director

Joengbin Ahn

Director Of Communications

Yunseon Chong

Director, Bd

Hyung Eun Kim

Director, Head Of Pharmacovigilance

Mikyoung Chang

Director, Scientific Affairs/ Scientific Liaison

Naeun Jeon

Director, Clinical Trial Leader, Global

Kyung Jin Kim

Director. Clinical Trial Leader

Kyungah Kim

Director

Company overview

Headquarters	58, Pangyo-ro 255 beon-gil, Bundang-gu, Suite 303, Seongnam-si, Gyeung-gi do 13486, KR
Website	bridgebiorx.com
NAICS	541714
SIC	283
Founded	2015
Employees	11-20
Socials

Bridge Biotherapeutics Email Formats

Bridge Biotherapeutics uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@bridgebiorx.com), used 41.7% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@bridgebiorx.com	41.7%
{first initial}.{last name}	j.doe@bridgebiorx.com	33.3%
{first initial}-.{last name}	j-.doe@bridgebiorx.com	16.7%
{last name}	doe@bridgebiorx.com	8.3%

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Director

Entry

Head

Employees by Department

Bridge Biotherapeutics has 4 employees across 3 departments.

Departments

Number of employees

Funding Data

Explore Bridge Biotherapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2017-02-01	1	N/A

Funding Insights

Number of funding rounds

Bridge Biotherapeutics Tech Stack

Discover the technologies and tools that power Bridge Biotherapeutics's digital infrastructure, from frameworks to analytics platforms.

Sectigo

SSL/TLS certificate authorities

Nginx

Reverse proxies

Microsoft 365

Frequently asked questions

Bridge Biotherapeutics is located in 58, Pangyo-ro 255 beon-gil, KR.

Bridge Biotherapeutics generates an estimated annual revenue of $1,625,545. This revenue figure reflects the company's market position and business performance in its industry.

Bridge Biotherapeutics has an estimated valuation of $5,300,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Bridge Biotherapeutics was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

Bridge Biotherapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.